UNITY Biotechnology, Inc. to Announce Second Quarter 2020 Financial Results
UNITY will not conduct a conference call in conjunction with the financial results press release.
About UNITY
UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby provide transformative benefit in age-related diseases, such as osteoarthritis, eye diseases, neurological diseases and pulmonary diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter.
Investors
mzanoni@enduranceadvisors.com
Media
jason@canalecomm.com
Source: Unity Biotechnology, Inc.